Last 48 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 224.37 | 129.05 | 315.62 | 350.67 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +75.8% | -96.9% | -63.8% | -46.3% | |
| P/B Ratio | 24.97 | 23.90 | 18.00 | 35.51 | 27.41 | 107.47 | 83.01 | 53.38 | 42.38 | 47.63 | 35.83 | 82.49 | 29.74 | 15.97 | 18.55 | 6.13 | 11.31 | 1.47 | 2.36 | 4.90 | 4.22 |
| — | -77.8% | -78.3% | -33.5% | -35.3% | +125.6% | +131.7% | -35.3% | +42.5% | +198.2% | +93.2% | +1245.8% | +163.0% | +988.0% | +686.7% | +25.2% | +168.1% | -77.6% | -70.3% | -53.1% | -30.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 68.84 | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -7700.0% | -5400.9% | -8863.2% | -10377.3% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -417.3% | +87.0% | -0.6% | -66.1% | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -9720.5% | -7136.6% | -8558.8% | -10796.5% |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -549.2% | +83.3% | +6.0% | -47.5% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -270.0% | -34.9% | -41.3% | -42.0% | -69.4% | -139.1% | -180.3% | -16.9% | -15.2% | -17.2% | -50.5% | -71.3% | -40.1% | -19.8% | -11.5% | -416.3% | -14.2% | -23.5% | -30.2% | -29.4% | -29.2% |
| — | +74.9% | +77.1% | -148.7% | -357.5% | -707.0% | -257.4% | +76.3% | +62.2% | +12.9% | -340.6% | +82.9% | -181.7% | +15.9% | +62.0% | -1316.1% | +51.2% | -31.2% | -13.7% | -21.6% | -28.0% | |
| ROA | -238.4% | -28.8% | -34.7% | -36.1% | -58.3% | -107.2% | -154.1% | -15.1% | -13.4% | -12.9% | -23.3% | -22.9% | -16.9% | -9.5% | -5.9% | -117.6% | -4.7% | -17.5% | -16.4% | -18.9% | -22.4% |
| — | +73.1% | +77.5% | -139.3% | -336.2% | -733.0% | -562.6% | +34.0% | +20.8% | -35.5% | -294.8% | +80.6% | -261.4% | +45.6% | +64.2% | -523.8% | +79.1% | -20.5% | +3.5% | -31.6% | -34.7% | |
| ROIC | -288.0% | -48.4% | -57.1% | -42.7% | -109.9% | — | -741.9% | -22.8% | -15.1% | -13.0% | -24.3% | -31.0% | -17.8% | -8.5% | -6.6% | -173.3% | -9.8% | -71.8% | -54.8% | -117.2% | -102.2% |
| — | — | +92.3% | -87.3% | -626.9% | — | -2953.5% | +26.5% | +15.3% | -52.2% | -265.5% | +82.1% | -81.5% | +88.1% | +87.9% | -47.9% | +90.4% | -2.2% | +43.4% | -48.6% | -80.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.04 | 0.03 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.07 | 0.56 | 2.48 | 1.37 | 1.07 | 0.90 | 0.78 | 4.10 | 0.03 | 0.53 | 0.43 | 0.03 |
| — | +25.3% | +51.2% | +95.9% | +70.8% | -62.0% | -96.2% | -99.2% | -98.6% | -93.1% | -37.9% | +217.4% | -66.7% | +3176.3% | +68.5% | +82.8% | +12161.7% | +82.4% | +2851.5% | -51.2% | +470.8% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 9.87 | 5.99 | 6.96 | 7.41 | 9.87 | 3.80 | 5.13 | 10.63 | 10.15 | 8.31 | 2.35 | 6.97 | 9.30 | 1.80 | 19.07 | 14.22 | 16.93 | 8.22 | 5.23 | 4.38 | 3.80 |
| — | +57.9% | +35.7% | -30.3% | -2.8% | -54.3% | +118.5% | +52.6% | +9.2% | +361.1% | -87.7% | -51.0% | -45.1% | -78.1% | +264.4% | +225.0% | +345.9% | +83.3% | -5.7% | +155.3% | -13.8% | |
| Quick Ratio | 9.87 | 5.99 | 6.96 | 7.41 | 9.87 | 3.80 | 5.13 | 10.63 | 10.15 | 8.31 | 2.35 | 6.97 | 9.30 | 1.80 | 19.07 | 14.22 | 16.93 | 8.22 | 5.23 | 4.38 | 3.80 |
| — | +57.9% | +35.7% | -30.3% | -2.8% | -54.3% | +118.5% | +52.6% | +9.2% | +361.1% | -87.7% | -51.0% | -45.1% | -78.1% | +264.4% | +225.0% | +345.9% | +83.3% | -5.7% | +155.3% | -13.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | -5430.70 | -16.14 | -11.38 | -10.04 | -8.90 | -5.40 | -3.61 | -1.58 | -3.73 | -26.67 | -20.10 | -106.16 | -18.05 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SMMT stock.
Summit Therapeutics Inc.'s current P/E is -15.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Summit Therapeutics Inc.'s business trajectory between earnings reports.